Yes, you are correct, a $3B BO would be hard for BP to "stomach", but I think it could happen, if the front end offering was handled properly. I am also ambivalent about a sale now for the same reason as yourself. RP influence, leadership, and the potential for Leronlimab to treat cancer have changed the "calculus" and licensing/partnership arrangements appear to be close.
News 
Market Data 
Discover 
